Cargando…

Phase II study of lonidamine in non-small cell lung cancer: final report.

Lonidamine (LND) is a new anti-cancer drug which interferes with the energy-yielding processes of tumour cells without affecting DNA replication. A total of 69 previously untreated patients with non-small cell lung cancer (NSCLC) entered this study. LND was given orally as a single agent at doses ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kokron, O., Maca, S., De Gregorio, M., Ciottoli, G. B.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1990
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971425/ https://www.ncbi.nlm.nih.gov/pubmed/2155644

Ejemplares similares

Phase II study of lonidamine in metastatic breast cancer.
por: Pronzato, P., et al.
Publicado: (1989)

A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
por: Mansi, J. L., et al.
Publicado: (1991)

Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine
por: Guo, Lili, et al.
Publicado: (2016)

Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis
por: Cheng, Gang, et al.
Publicado: (2019)

New Organometallic Ru(II) Compounds with Lonidamine Motif as Antitumor Agents
por: Shutkov, Ilya A., et al.
Publicado: (2023)

Ru(III) Complexes with Lonidamine-Modified Ligands
por: Shutkov, Ilya A., et al.
Publicado: (2021)

Inhibition of the recovery from potentially lethal damage by lonidamine.
por: Hahn, G. M., et al.
Publicado: (1984)

The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment
por: Huang, Yaxin, et al.
Publicado: (2020)

Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases
por: Chen, Chen, et al.
Publicado: (2022)

Effect of lonidamine derivatives on the inhibition of transformed cell area expansion
por: Aoyama, Megumi, et al.
Publicado: (2023)

Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.
por: Silvestrini, B., et al.
Publicado: (1983)

Cu(I) and Cu(II) Complexes Based on Lonidamine-Conjugated Ligands Designed to Promote Synergistic Antitumor Effects
por: Del Bello, Fabio, et al.
Publicado: (2022)

Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line.
por: Citro, G., et al.
Publicado: (1991)

Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine
por: Bhutia, Yangzom D., et al.
Publicado: (2016)

Amplification of anticancer efficacy by co-delivery of doxorubicin and lonidamine with extracellular vesicles
por: Li, Huizhen, et al.
Publicado: (2022)

Discovering a Reversible Male Contraceptive Agent Derived from Lonidamine
por: Gong, Shengnan, et al.
Publicado: (2023)

Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin
por: Nath, Kavindra, et al.
Publicado: (2018)

Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer
por: Wang, Zhongjie, et al.
Publicado: (2023)

In vitro effects of lonidamine and 6-aminonicotinamide against Echinococcus granulosussensu stricto and Echinococcus multilocularis
por: Xin, Qi, et al.
Publicado: (2020)

The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease
por: Sundar, Shirin V., et al.
Publicado: (2022)

Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts.
por: De Cesare, M., et al.
Publicado: (1998)

Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy
por: Cervantes-Madrid, Diana, et al.
Publicado: (2015)

Lonidamine and domperidone inhibit expansion of transformed cell areas by modulating motility of surrounding nontransformed cells
por: Aoyama, Megumi, et al.
Publicado: (2022)

pH-dependent structural characteristics of lonidamine: (1)H and (13)C NMR study
por: Gupta, Pradeep Kumar, et al.
Publicado: (2023)

Therapeutic Efficacy and Safety of Paclitaxel/Lonidamine Loaded EGFR-Targeted Nanoparticles for the Treatment of Multi-Drug Resistant Cancer
por: Milane, Lara, et al.
Publicado: (2011)

Mitochondrial Targeting and pH-Responsive Nanogels for Co-Delivery of Lonidamine and Paclitaxel to Conquer Drug Resistance
por: Chen, Enping, et al.
Publicado: (2021)

Lonidamine potentiates the oncolytic efficiency of M1 virus independent of hexokinase 2 but via inhibition of antiviral immunity
por: Cai, Jing, et al.
Publicado: (2020)

LC-MS based stability-indicating method for studying the degradation of lonidamine under physical and chemical stress conditions
por: Rochani, Ankit Kanaiyalal, et al.
Publicado: (2020)

In Vitro Effect of Mitochondria-Targeted Triphenylphosphonium-Based Compounds (Honokiol, Lonidamine, and Atovaquone) on the Platelet Function and Cytotoxic Activity
por: Montecino-Garrido, Héctor, et al.
Publicado: (2022)

Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice
por: Nath, Kavindra, et al.
Publicado: (2016)

The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes
por: Davidescu, Magdalena, et al.
Publicado: (2015)

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer
por: Sørensen, J B, et al.
Publicado: (1999)

Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial
por: Yoshida, Tatsuya, et al.
Publicado: (2023)

Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials Committee.
por: Kaye, S. B., et al.
Publicado: (1992)

Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2019)

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
por: Yamamoto, Noboru, et al.
Publicado: (2016)

A phase II study of high dose epirubicin in unresectable non small cell lung cancer.
por: Smit, E. F., et al.
Publicado: (1992)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer
por: Belani, Chandra P, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8jml9cjob2015gdcvjjbg8psl9